Related Experiment Video

Updated: Jun 19, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and

David K Finlay1, Linda V Sinclair, Carmen Feijoo

  • 1Division of Immunology and Cell Biology, University of Dundee, Dundee DD15EH, Scotland, UK.

The Journal of Experimental Medicine
|October 8, 2009
PubMed

Insights

Phosphoinositide-dependent kinase 1 (PDK1) is crucial for T cell lymphoma development when the PTEN tumor suppressor is deleted. PTEN deletion bypasses normal growth controls but PDK1 still regulates signaling and cell migration in these cancerous T cells.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Phosphoinositide-dependent kinase 1 (PDK1) signaling is vital for normal T cell progenitor function, regulating protein kinase B (PKB) activation and subsequent inactivation of Foxo transcription factors, thereby controlling cell growth and proliferation.
  • The tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) plays a critical role in preventing uncontrolled cell growth and cancer development.

Purpose of the Study:

  • To investigate the role of PDK1 in lymphomagenesis resulting from PTEN deletion in T cell progenitors.
  • To elucidate how PTEN loss affects PDK1-mediated signaling pathways governing T cell growth, proliferation, and migration.

Main Methods:

  • Characterization of PDK1's function in T cell progenitors with experimentally deleted PTEN.
  • Analysis of signaling pathways, including PKB-Foxo axis, in PTEN-null thymocytes.
  • Assessment of adhesion and chemokine receptor expression in PTEN-null T cells.

Main Results:

  • PDK1 is essential for lymphomagenesis driven by PTEN deletion in T cell progenitors.
  • PTEN deletion circumvents canonical PDK1-controlled pathways regulating thymocyte growth and proliferation.
  • PDK1 remains critical in PTEN-null thymocytes for controlling the PKB-Foxo axis and dictating the expression of adhesion and chemokine receptors, influencing migratory capacity.

Conclusions:

  • PTEN loss in lymphocytes bypasses normal PDK1-mediated metabolic checkpoints governing cell growth and proliferation.
  • PDK1 critically influences the migratory behavior of PTEN-null lymphocytes by regulating their chemokine and adhesion receptor profiles.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...